Literature DB >> 21590352

[Drug therapy and radiotherapy in Graves' orbitopathy].

F Beisse1, W A Lagrèze, M Schmucker.   

Abstract

Drug therapy and radiotherapy in Graves' orbitopathy (GO) aim mainly at the inherent soft tissue inflammation. A timely and sustained anti-inflammatory therapy not only alleviates the current symptoms but particularly intends to limit the degree of permanent alterations. It is indicated in active GO of moderate or higher severity. Pharmacologically, glucocorticoids and if appropriate other immunosuppressive agents, such as cyclosporine are given. Adverse effects can complicate the treatment. Retrobulbar irradiation is applied against diplopia due to eye muscle involvement during the active phase.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21590352     DOI: 10.1007/s00347-010-2187-7

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  31 in total

1.  Radiotherapy of non-malignant disorders: where do we stand?

Authors:  Jan Willem Leer; Paul van Houtte; Heinrich Seegenschmiedt
Journal:  Radiother Oncol       Date:  2007-05-08       Impact factor: 6.280

2.  Botulinum toxin A induced protective ptosis.

Authors:  G G Adams; C M Kirkness; J P Lee
Journal:  Eye (Lond)       Date:  1987       Impact factor: 3.775

3.  Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument.

Authors:  M N Gerding; C B Terwee; F W Dekker; L Koornneef; M F Prummel; W M Wiersinga
Journal:  Thyroid       Date:  1997-12       Impact factor: 6.568

4.  A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy.

Authors:  C A Gorman; J A Garrity; V Fatourechi; R S Bahn; I A Petersen; S L Stafford; J D Earle; G S Forbes; R W Kline; E J Bergstralh; K P Offord; D M Rademacher; N M Stanley; G B Bartley
Journal:  Ophthalmology       Date:  2001-09       Impact factor: 12.079

5.  Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection.

Authors:  Jimmy M Uddin; Peter D Davies
Journal:  Ophthalmology       Date:  2002-06       Impact factor: 12.079

6.  Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy.

Authors:  A Jane Dickinson; Bijay Vaidya; Margaret Miller; Alan Coulthard; Petros Perros; Elizabeth Baister; Christopher D Andrews; Lutz Hesse; Johannes T Heverhagen; Armin E Heufelder; Pat Kendall-Taylor
Journal:  J Clin Endocrinol Metab       Date:  2004-12       Impact factor: 5.958

7.  A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy.

Authors:  Mark F Prummel; Caroline B Terwee; Martin N Gerding; Lelio Baldeschi; Maarten P Mourits; Leo Blank; Friedo W Dekker; Wilmar M Wiersinga
Journal:  J Clin Endocrinol Metab       Date:  2004-01       Impact factor: 5.958

8.  Ciamexone in endocrine orbitopathy. A randomized double-blind, placebo-controlled study.

Authors:  G Kahaly; W Lieb; W Müller-Forell; M Mainberger; J Beyer; J Vollmar; C Staiger
Journal:  Acta Endocrinol (Copenh)       Date:  1990-01

9.  Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone.

Authors:  L Bartalena; C Marcocci; L Chiovato; M Laddaga; G Lepri; D Andreani; G Cavallacci; L Baschieri; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  1983-06       Impact factor: 5.958

Review 10.  [Botulinum toxin treatment for crocodile tears, spastic entropion and for dysthyroid upper eyelid retraction].

Authors:  B Wabbels; M Förl
Journal:  Ophthalmologe       Date:  2007-09       Impact factor: 1.174

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.